Ocular Therapeutix (OCUL)

• Market cap: $1.34B
• 1 day: 0.59%
• 5 days: -3.41%
• 1 month: -3.19%
• 3 months: -5.35%
• 6 months: 39.80%
• Year to date: 76.72%
• 1 year: 116.84%
• 5 years: 111.44%
• 10 years: -61.80%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Employees: 267

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

106% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 17

43% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]

23% more capital invested

Capital invested by funds: $989M [Q2] → $1.22B (+$230M) [Q3]

12% more funds holding

Funds holding: 149 [Q2] → 167 (+18) [Q3]

3.64% less ownership

Funds ownership: 93.4% [Q2] → 89.76% (-3.64%) [Q3]

16% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 49

26% less call options, than puts

Call options by funds: $2.34M | Put options by funds: $3.17M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 76% upside
• Avg. target: $18.50 118% upside
• High target: $22 159% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target	76% upside $15	Buy Reiterated	3 Dec 2024
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target	159% upside $22	Sector Outperform Initiated	16 Oct 2024